AbbVie Inc. Files Routine 8-K Report
Ticker: ABBV · Form: 8-K · Filed: Sep 10, 2024 · CIK: 1551152
| Field | Detail |
|---|---|
| Company | Abbvie Inc. (ABBV) |
| Form Type | 8-K |
| Filed Date | Sep 10, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: routine-filing, corporate-governance, financial-reporting
Related Tickers: ABBV
TL;DR
ABBV filed a standard 8-K, no major news.
AI Summary
On September 6, 2024, AbbVie Inc. filed an 8-K report detailing amendments to its articles of incorporation or bylaws and financial statements. The filing does not disclose specific new financial figures or material events beyond routine reporting requirements.
Why It Matters
This filing serves as a standard update for investors, confirming routine corporate actions and financial reporting without indicating any immediate significant changes to the company's operations or financial health.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain information about any significant new risks or material adverse events.
Key Players & Entities
- AbbVie Inc. (company) — Filer of the 8-K report
- 0001104659-24-098564 (document_id) — Accession number for the filing
- 20240906 (date) — Date of the earliest event reported
FAQ
What is the primary purpose of this 8-K filing by AbbVie Inc.?
The primary purpose of this 8-K filing is to report amendments to AbbVie Inc.'s articles of incorporation or bylaws and to file financial statements and exhibits.
What is the accession number for this 8-K filing?
The accession number for this 8-K filing is 0001104659-24-098564.
On what date was this 8-K report filed?
This 8-K report was filed on September 10, 2024.
What is AbbVie Inc.'s fiscal year end?
AbbVie Inc.'s fiscal year end is December 31.
Does this filing indicate any new material events or financial changes?
Based on the provided text, this filing appears to be routine and does not explicitly detail any new material events or significant financial changes beyond standard reporting requirements.
Filing Stats: 612 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-09-10 15:30:45
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 Par Value ABBV New York Stock Excha
Filing Documents
- tm2423380d1_8k.htm (8-K) — 41KB
- tm2423380d1_ex3-1.htm (EX-3.1) — 192KB
- 0001104659-24-098564.txt ( ) — 535KB
- abbv-20240906.xsd (EX-101.SCH) — 5KB
- abbv-20240906_def.xml (EX-101.DEF) — 30KB
- abbv-20240906_lab.xml (EX-101.LAB) — 44KB
- abbv-20240906_pre.xml (EX-101.PRE) — 28KB
- tm2423380d1_8k_htm.xml (XML) — 12KB
03 Amendment to Articles of Incorporation or Bylaws; Change
Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year On September 6, 2024, the Board of Directors of AbbVie Inc. (the "Company") approved an amendment and restatement of the Company's By-laws (the "Third Amended and Restated By-laws"), effective as of such date. The amendments set forth in the Third Amended and Restated By-laws, (1) update the address of Company's registered agent, and (2) delete section 2.13(D)(iv) in its entirety. Company is the defendant in a stockholder class action complaint challenging the lawfulness of Section 2.13(D)(iv). Company believes the provision is lawful but no longer has any practical value to the Company. Accordingly, Company does not believe defending this provision is the best use of company resources. The foregoing summary of the Third Amended and Restated By-laws does not purport to be complete and is qualified in its entirety by reference to the full text of the Third Amended and Restated By-laws, which is attached as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit 3.1 Third Amended and Restated By-laws of AbbVie Inc. adopted September 6, 2024. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: September 10, 2024 By: /s/ Perry C. Siatis Perry C. Siatis Executive Vice President, General Counsel and Secretary